![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, February 25, 2021 1:18:21 PM
It's good given that one of the very few remaining therapeutic competitors has stumbled.
It's bad if it indicates that HGEN's antibody will suffer a similar fate, since they are both anti-GM-CSF.
The HGEN trial may do a lot better if their antibody is better-engineered (as HGEN claims in general), or if GSK's dosing regimen was poorly chosen due to lack of experience and risk-aversion (HGEN had a number of earlier trials supporting safety and efficacy that may have led to better dosing decisions), or if GSK's allowed use on ventilated patients horribly distorted their study (HGEN avoids giving their drug to ventilated patients), or if HGEN's endpoints are better chosen, or if .....
Any experts out there who would like to chime in?
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM